Monocytes and Neutrophils as ‘Bad Guys’ for the Outcome of Interleukin-2 With and Without Histamine in Metastatic Renal Cell Carcinoma – Results From a Randomised Phase II Trial

British Journal of Cancer - United Kingdom
doi 10.1038/sj.bjc.6602937
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Nature

Related search

Two Randomised Phase II Trials of Subcutaneous Interleukin-2 and Histamine Dihydrochloride in Patients With Metastatic Renal Cell Carcinoma

British Journal of Cancer
Cancer ResearchOncology
2005English

Perioperative Immunomodulation With Interleukin-2 in Patients With Renal Cell Carcinoma: Results of a Controlled Phase II Trial

British Journal of Cancer
Cancer ResearchOncology
2006English

A Phase I/Ii Trial of BNC105P With Everolimus in Metastatic Renal Cell Carcinoma

Clinical Cancer Research
Cancer ResearchOncology
2015English

Recombinant Human Interleukin 6 in Metastatic Renal Cell Cancer: A Phase II Trial

British Journal of Cancer
Cancer ResearchOncology
1996English

A Randomised Dose Escalation Study of Subcutaneous Interleukin 2 With and Without Levamisole in Patients With Metastatic Renal Cell Carcinoma or Malignant Melanoma

British Journal of Cancer
Cancer ResearchOncology
1996English

Phase II Trial of Capecitabine and Weekly Docetaxel in Metastatic Renal Cell Carcinoma

Urology
Urology
2008English

Sorafenib With Interleukin-2 vs Sorafenib Alone in Metastatic Renal Cell Carcinoma: The ROSORC Trial

British Journal of Cancer
Cancer ResearchOncology
2011English

Anlotinib Versus Sunitinib as First‐Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial

Oncologist
Cancer ResearchMedicineOncology
2019English

Phase I Trial of Sunitinib and Temsirolimus in Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy